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Abstract
Background: In uncontrolled before-after studies, CONSORT was shown to improve the reporting of randomised trials.
Before-after studies ignore underlying secular trends and may overestimate the impact of interventions. Our aim was to
assess the impact of the 2007 STROBE statement publication on the quality of observational study reporting, using both
uncontrolled before-after analyses and interrupted time series.
Methods: For this quasi-experimental study, original articles reporting cohort, case-control, and cross-sectional studies
published between 2004 and 2010 in the four dermatological journals having the highest 5-year impact factors ($4) were
selected. We compared the proportions of STROBE items (STROBE score) adequately reported in each article during three
periods, two pre STROBE period (2004–2005 and 2006–2007) and one post STROBE period (2008–2010). Segmented
regression analysis of interrupted time series was also performed.
Results: Of the 456 included articles, 187 (41%) reported cohort studies, 166 (36.4%) cross-sectional studies, and 103 (22.6%)
case-control studies. The median STROBE score was 57% (range, 18%–98%). Before-after analysis evidenced significant
STROBE score increases between the two pre-STROBE periods and between the earliest pre-STROBE period and the post-
STROBE period (median score2004–05 48% versus median score2008–10 58%, p,0.001) but not between the immediate pre-
STROBE period and the post-STROBE period (median score2006–07 58% versus median score2008–10 58%, p= 0.42). In the pre
STROBE period, the six-monthly mean STROBE score increased significantly, by 1.19% per six-month period (absolute
increase 95%CI, 0.26% to 2.11%, p= 0.016). By segmented analysis, no significant changes in STROBE score trends occurred
(20.40%; 95%CI, 22.20 to 1.41; p= 0.64) in the post STROBE statement publication.
Interpretation: The quality of reports increased over time but was not affected by STROBE. Our findings raise concerns
about the relevance of uncontrolled before-after analysis for estimating the impact of guidelines.
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Introduction
The randomised controlled design is the reference standard for
evaluating the efficacy of new treatments but cannot answer all
important questions about a given intervention. Observational
studies may be better able to detect rare or delayed adverse effects
of treatments and to reflect outcomes obtained in everyday
practice [1]. However, the reporting of observational research may
be insufficiently accurate or clear to enable assessments of the
strengths and weaknesses of the available evidence [2,3]. To
improve the reporting of observational cohort, case-control, and
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cross-sectional studies, a group of experts developed a checklist of
22-items, which was published in 2007 as the STrengthening the
Reporting of OBservational Studies in Epidemiology (STROBE)
statement [4,5,6,7,8,9,10]. A few studies used STROBE to assess
the quality of observational study reporting [11,12]; however, the
impact of STROBE on the quality of observational study
reporting has never been assessed excepted 2 randomized
studies assessing the impact of adding the STROBE
checklist to conventional review on manuscript quality
[13,14]. According to uncontrolled before-after studies, the 1996
CONsolidated Standards of Reporting Trials (CONSORT)
statement improved the reporting of randomised trials
[15,16,17]. However, the uncontrolled before-after design fails to
take underlying secular trends into account, which may result in
overestimation of the impact of interventions [18,19]. Further-
more, reporting quality is generally assessed in leading generalist
medical journals with very high impact factors (IF), whereas most
studies are published in specialist journals.
The goals of this study were to test the hypotheses that the
quality of observational study reporting improved over time and
that the generally used uncontrolled before-after design was
inadequate for assessing whether STROBE statement publication
affected this improvement. We assessed the quality of observa-
tional study reporting between 2004 and 2010 in the four
dermatological journals with the highest 5-year IFs.
Figure 1. Flow diagram.
doi:10.1371/journal.pone.0064733.g001
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Table 1. Proportion of adequate reporting of the 22 items of the STROBE statement in the 456 articles analyzed.
Item No Recommendation N (%)
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract 296 (64.9)
(b) Provide in the abstract an informative and balanced summary of what was done
and what was found
Introduction
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported 402 (88.2)
Objectives 3 State specific objectives, including any prespecified hypotheses 396 (86.8)
Methods
Study design 4 Present key elements of study design early in the paper 210 (46.1)
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment,
exposure, follow-up, and data collection
352 (77.2)
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection
of participants. Describe methods of follow-up Case-control study—Give the eligibility
criteria, and the sources and methods of case ascertainment and control selection.
Give the rationale for the choice of cases and controls Cross-sectional study—Give the
eligibility criteria, and the sources and methods of selection of participants
348 (76.3)
(b) Cohort study—For matched studies, give matching criteria and number of exposed
and unexposed Case-control study—For matched studies, give matching criteria and
the number of controls per case
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect
modifiers. Give diagnostic criteria, if applicable
227 (49.9)
Data sources/measurement 8* For each variable of interest, give sources of data and details of methods of
assessment (measurement). Describe comparability of assessment methods if there
is more than one group
339 (74.3)
Bias 9 Describe any efforts to address potential sources of bias 124 (27.2)
Study size 10 Explain how the study size was arrived at 19 (4.5)
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable,
describe which groupings were chosen and why
174 (42.1)
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding 73 (16)
(b) Describe any methods used to examine subgroups and interactions
(c) Explain how missing data were addressed
(d) Cohort study—If applicable, explain how loss to follow-up was addressed
Case-control study—If applicable, explain how matching of cases and controls was
addressed Cross-sectional study—If applicable, describe analytical methods taking
account of sampling strategy
(e) Describe any sensitivity analyses
Results
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially
eligible, examined for eligibility, confirmed eligible, included in the study, completing
follow-up, and analysed
124 (33.2)
(b) Give reasons for non-participation at each stage
(c) Consider use of a flow diagram
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and
information on exposures and potential confounders
274 (60.8)
(b) Indicate number of participants with missing data for each variable of interest
(c) Cohort study—Summarise follow-up time (eg, average and total amount)
Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time 145 (92.4)
Case-control study—Report numbers in each exposure category, or summary
measures of exposure
Cross-sectional study—Report numbers of outcome events or summary measures
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and
their precision (eg, 95% confidence interval). Make clear which confounders were
adjusted for and why they were included
284 (62.8)
(b) Report category boundaries when continuous variables were categorized
(c) If relevant, consider translating estimates of relative risk into absolute risk for a
meaningful time period
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and
sensitivity analyses
170 (38.5)
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Methods
For this quasi-experimental study, we selected the four
dermatology journals with the highest 5-year IFs in the 2010
Journal Citation Report, namely, the Journal of Investigative
Dermatology (IF, 5.76), the British Journal of Dermatology (IF, 4.24),
the Journal of the American Academy of Dermatology (IF, 4.16), and the
Archives of Dermatology (IF, 3.98). Pigment Cell and Melanoma Research
(IF, 4.64) was not included because this journal publishes nearly
only experimental studies.
Data selection
We selected all articles published between January 2004 and
December 2010 that reported cohort, case-control, or cross-
sectional studies. We did not include non-original studies,
experimental and basic science studies, meta-analyses, letters, or
studies in categories having their own reporting guidelines,
namely, diagnostic and genetic studies (STARD and STREGA,
respectively).
To identify eligible studies, we conducted a PubMed search of
Medline and we manually searched all issues of each journal
published during the study period. The indexing terms used for the
electronic search were ((‘‘Case-Control Studies’’[Mesh] OR
‘‘Cohort Studies’’[Mesh] OR ‘‘Cross-Sectional Studies’’[Mesh])
AND (‘‘the British Journal of Dermatology’’ [journal] OR ‘‘the
Journal of the American Academy of Dermatology’’ [journal] OR
‘‘the Archives of Dermatology’’ [journal] OR ‘‘the Journal of
Investigative Dermatology’’ [journal]) NOT ‘‘Randomized Con-
trolled Trial’’[Publication Type]) with limits: ‘‘humans, only items
with abstracts, English’’. The titles and abstracts were screened by
two of us (SBG and ES) working independently of each other and
resolving disagreements by consensus, which led to the selection of
560 articles (Figure 1). The names and affiliations of the authors
and the dates of article acceptance and publication were masked to
minimise evaluation bias.
Data abstraction
To standardise the data abstraction process and to determine
whether further clarification of STROBE item scoring was
needed, all of us performed a pilot experiment consisting in
abstracting data from 25 articles. All articles were then allocated at
random to pairs of investigators; each pair was composed of a
physician specialised in clinical epidemiology (PhD) and a
dermatologist. Discrepancies were reviewed within the pairs and
resolved by consensus if possible; if not, one of us (SBG) served as
the arbitrator. To avoid potential bias due to working in pairs and
to ensure consistency in the review process throughout the study, a
permutation scheme was used to modify the pairs. Permutation
scheme permitted to disseminate learning and to
improve pair performance.
The investigators abstracted the 22 items of the STROBE
checklist by answering 57 questions (online supplement) adapted
from those used by Langan et al. [11] Four response options were
available for each of the 57 questions: ‘yes’, ‘in part or unclear’,
‘no’, and ‘not applicable’. The acceptance year and publication
year of each article were extracted by one of us (SBG), who was
blinded to the checklist answers. Data were collected using an
electronic case-report form established specifically for the study
(CleanWEB, Telemedicine Technologies S.A.–2007).
Outcome measure
The primary outcome was the STROBE score, defined as the
number of the 22 STROBE items adequately reported divided by
the number of applicable items, expressed as a percentage. The 13
STROBE items with several questions (2 to 15 questions per item,
online supplement) were considered adequately reported when at
least 50% of their questions had ‘yes’ answers (after exclusion of
the ‘not applicable’ components) [11].
This study did not require approval by an ethics committee,
since it concerned publications and not individuals.
Data analysis
Quantitative variables are reported as median (interquartile
range) and qualitative variables as number (percentage).
Uncontrolled before-after analysis. We used the Mann-
Whitney test with Bonferroni’s correction to compare STROBE
scores of articles published in 2004–5 (early pre-STROBE period)
and 2008–10 (post-STROBE period). Then, we compared the
early and immediate pre-STROBE periods (2004–5 versus 2006–7)
and the immediate pre-STROBE and post-STROBE periods
(2006–7 versus 2008–10). We assessed the a posteriori power.
Interrupted time series analysis. We used a segmented
linear regression model to determine the impact of STROBE over
time [18,19,20]. We considered two periods, the pre-STROBE
period (from the first semester of 2004 to the second semester of
2007) and the post-STROBE period (from the first semester of
2008 to the second semester of 2010). Because we hypothesised
that STROBE statement dissemination increased gradually over
time, we did not consider a dissemination segment for the
principal analysis.
Table 1. Cont.
Item No Recommendation N (%)
Discussion
Key results 18 Summarise key results with reference to study objectives 326 (71.5)
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or
imprecision. Discuss both direction and magnitude of any potential bias
208 (45.6)
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations,
multiplicity of analyses, results from similar studies, and other relevant evidence
210 (46)
Generalisability 21 Discuss the generalisability (external validity) of the study results 127 (28.2)
Other information
Funding 22 Give the source of funding and the role of the funders for the present study and,
if applicable, for the original study on which the present article is based
278 (61)
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.
doi:10.1371/journal.pone.0064733.t001
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The dependent variable was the six-month STROBE score
mean. A period of six months was chosen to obtain at least 30
observations per point. The independent variable was the semester
and year of publication.
The segmented regression model included an intercept (a1), a
baseline trend (b1), and a change of trend after STROBE
publication (b2). The level and trend of the pre-STROBE segment
(2004–2007) served as the control for the post-STROBE segment
(2008–2010). We estimated the difference between pre-STROBE
and post-STROBE slopes and the six-monthly mean STROBE
effect after STROBE publication. Independence of residuals was
tested using the autocorrelation function and the Durbin-Watson
test. Similar analyses stratified by journal were performed.
Sensitivity analyses. Similar analyses were also performed
using two sensitivity-STROBE scores. For the first score, ‘‘partly’’
answers were analysed as ‘‘yes’’ answers. The second score
considered the proportion of the 57 STROBE-derived questions
that were adequately answered. For this score, 1 was assigned to
‘yes’ answers and 0.5 to ‘in part or unclear’ answers to obtain a
sum that was then divided by the number of applicable questions.
Similar analyses were performed with the post-STROBE period
restricted to 2009–10 and with three periods, a pre-STROBE
period (2004–2007), a dissemination period (2008), and a post-
STROBE period (2009–2010) (interrupted time series). Last,
similar analyses were performed using non pooled data
(with the dependant variable being the STROBE score
per article).
All tests were two-tailed, and p values ,0.05 were considered
significant.
Data were analysed using STATA v11.0 (College Station, TX,
USA) and SAS v9.3 (SAS Institute, Cary, NC, USA) software.
Results
Of the 560 initially selected articles, 104 (18.6%) were excluded
after reviewing the full publication because they were not relevant
to the study (86 case-series, 11 interventional studies, 5 genetic
studies, and 2 diagnostic studies). Figure 1 shows the flow diagram.
The list of articles is provided in the online supplement.
The remaining 456 articles reported 187 (41%) cohort studies,
166 (36.4%) cross-sectional studies, and 103 (22.6%) case-control
studies. The median number of articles per year was 63 (range 47
to 91). The median STROBE score was 57% (range 18 to 98%).
Details regarding the reporting of the different items of
STROBE are available on Table 1. Table 2 displays the
median STROBE score values over time. There were no missing
data.
The STROBE items adequately reported in less than 50% of
articles were sample size estimation (5% of adequate reporting),
statistical methods (16%), description of efforts to limit potential
sources of bias (27%), discussion of external validity (28%),
number of participants at each stage (33%), statistical treatment of
quantitative variables (42%), and discussion of limitations (46%).
Before-after analysis
The STROBE score increased significantly from the early pre-
STROBE period to the post-STROBE period (median score2004–
05 48% versus median score2008–10 58%, p,0.001) and between the
two pre-STROBE periods (Table 2). Conversely, STROBE scores
did not change significantly between the immediate pre-STROBE
period (2006–7) and the post-STROBE period (median score2006–
07 58% versus median score2008–10 58%, p= 0.42).
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Similar results were obtained with the sensitivity-STROBE
scores, and with the post-STROBE period restricted to 2009–10
(data not shown).
Time series analysis
In the pre STROBE statement publication period, the mean
STROBE score increased significantly, by 1.19% per six-month
period (95% confidence interval [95%CI] of the absolute increase,
0.26% to 2.11%, p= 0.016) (Figure 2). This trend did not change
significantly after publication of the STROBE statement (absolute
change, 20.40%; 95%CI, 22.20 to 1.41; p= 0.64).
Table 3 reports the baseline trend and change in trend after
STROBE statement publication using the full linear segmented
model and the most parsimonious model consisting in simple
linear regression after elimination of non-significant terms (change
between the before and after periods). Our final model was neither
corrected for seasonal variations (not applicable) nor adjusted for
autocorrelation (residuals were independent, normally distributed,
with mean zero and constant variance). Finally, the six-monthly
mean STROBE score increased by 1.01% (absolute increase
95%CI, 0.58% to 1.44%, p,0.001).
In stratified analyses, the baseline STROBE score differed
across journals, but the trends were almost similar across the four
journals (Figure S1 online supplement).
Results were very similar with the sensitivity-STROBE scores or
with a dissemination period (data not shown). In the non pooled
analyses, the STROBE score per article increased
significantly, by 2.1% per year (95%CI of the absolute
increase, 1.3% to 2.8%, p,1024).
A posteriori power. Based on the sample size includ-
ing in the 3 periods 110, 125 and 221 articles respectively
and a mean STROBE score of 50/100 with a standard
deviation of 15, we were able to detect a 5 points
increase with a power of 80%.’’
Interpretation
We found that reporting was inadequate in a large proportion of
articles published from 2004 to 2010, the median STROBE score
being 57%. Reporting rates were lowest for sample size estimation,
description of statistical methods and of efforts to limit potential
sources of bias, discussion of external validity, and discussion of
limitations. By uncontrolled before-after analysis, the STROBE
score increased significantly between the early pre-STROBE
period (2004–5) and 2008–10 but not between the immediate pre-
STROBE period (2006–7) and 2008–10. Interrupted time series
analysis showed a significant STROBE score increase over time
that was not influenced by the publication of STROBE.
The few studies assessing the quality of observational study
reporting, with the STROBE statement as a reference, identified a
number of deficiencies consistent with our findings, including
marked inadequacies in reporting the management of missing data
[11,12,21,22], confounding [21,22], and sample size [11,21,22].
The global STROBE score for 2006–2007 of 58% was close to the
median number of reported items per article found by Langan et
al. (59%, 55%, and 55% for cohort, cross-sectional, and case-
control studies, respectively) in five dermatology journals (2005–
2007) [11]. Interestingly, somewhat higher global STROBE scores
were reported for studies in leading generalist journals (69% in
Figure 2. Time series of six-monthly mean STROBE scores and values predicted from the segmented and simple linear regression
models.
doi:10.1371/journal.pone.0064733.g002
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2010) [22], in accordance with the lower and delayed compliance
with CONSORT in specialty publications compared to generalist
journals such as the New England Journal of Medicine or The Lancet
[23]. Although the general applicability of our findings from
dermatology journals may be debatable, we believe that assessing
reporting quality in specialist journals is crucial, since these
journals account for the majority of studies that are published and
read by specialists on a regular basis. None of the studies assessing
quality of observational study reporting [11,12,21,22] evaluated
the impact of STROBE statement publication. Several studies
suggested that using the CONSORT statement might improve the
reporting of randomised controlled trials [15,16,17,24]. However,
all these studies used the uncontrolled before-after design. Previous
evidence suggests that uncontrolled before-after analyses compar-
ing two time periods may overestimate the effects of interventions
designed to improve quality [18]. In keeping with this
possibility, our before-after analysis showed a significant
improvement between two time points in the pre and post
STROBE statement publication periods. Interrupted time
series analysis is a strong quasi-experimental method for
distinguishing the baseline trend from the effect of interventions
in longitudinal studies [19,20]. A well-designed time series
analysis increases the confidence with which the estimated effect
can be attributed to the intervention, although it does not
separate the intervention-related effect from the potential effects
of other events occurring at the same time [18].
Our study did not support evidence of a significant
impact of STROBE statement publication during the
study period. It may be related to two main factors. First,
STROBE was published at a time of continuous improvements in
reporting quality in medical journals, extending across all study
designs, which may have masked additional subtle benefits related
to STROBE. Second, our research covers only the first three years
after STROBE publication. It would be of interest to evaluate
subsequent trends, particularly given the recent endorsement of
the STROBE statement by two of the four journals included in
our study (British Journal of Dermatology and Journal of the American
Academy of Dermatology). Endorsement of a reporting guideline by a
journal may have a greater impact on reporting quality in that
journal than publication of the guideline. However, during our
study period, none of the four journals had endorsed STROBE, in
keeping with most other medical journals. We aimed to analyse
penetration of STROBE and not its endorsement by journals.
Moreover, in a comparison of the quality of reporting of
randomised controlled trials in four journals, of which three
required the use of CONSORT from 1996 onwards (JAMA, British
Medical Journal, The Lancet) and one did not (New England Journal of
Medicine), a before-after analysis indicated an improvement in
quality between 1994 and 1998 in all four journals [15].
Limitations
We did not analyse agreement between the pairs of reviewers,
but the permutation scheme used to modify the pairs limited
potential bias related to working in pairs while ensuring
consistency in the review process throughout the study. We used
a global score for each article to provide a measure of overall
reporting. In choosing this method, we do not suggest that all items
are of equal importance. We built two sensitivity-STROBE scores;
the consistency of the sensitivity analysis results with the main
analysis supports the robustness of our findings.
The factor with the strongest influence on the quality of time
series analysis is the number of data points collected in the pre-
intervention period (estimation of trend) and in the post
intervention period (estimation of the intervention effect)
[19,20]. We considered only eight data points in the pre-STROBE
period, but this number is higher than the three data points
recommended by the Cochrane Effective Practice and Organisation
of Care group to obtain a stable underlying secular trend [25].
Conclusion
This study highlights continuing deficiencies in the reporting of
observational studies in dermatology journals despite improvements
over time (2004–2010). Our results suggest that publication of the
STROBE statement may have failed to significantly influence the
quality of observational study reporting during the first three years.
Moreover, we illustrated that the uncontrolled before-after design
may produce inaccurate results regarding the impact of study
reporting guidelines. The impact of reporting guidelines should be
assessed using the adequate methods currently used for assessing
medical practice guidelines or public health interventions.
Supporting Information
Figure S1 Time series of annual mean STROBE scores
and values predicted from simple linear regression
models stratified by journal. The y axis shows the annual
mean STROBE score by journal and the x axis the year.
(TIF)
Table 3. Parameter estimates from the full and most parsimonious final linear regression models predicting the mean six-monthly
STROBE score per article.
Estimate coefficient (standard deviation) p value
Full model (segmented linear regression)
1st segment (pre-STROBE, 1st half of 2004 to 2nd half of 2007)
Intercept a1 47.5 (2.31) ,0.001
Baseline trend b1 1.19 (0.42) 0.016
2nd segment (post-STROBE, 1st half of 2008 to 2nd half of 2010)
Trend change b2 20.40 (0.82) 0.64
Final model (Simple linear regression){
Intercept 48.2 (1.69) ,0.001
Trend change b1 1.01 (0.20) ,0.001
{The final model (i.e., the most parsimonious model) included all the terms significant in the segmented model.
doi:10.1371/journal.pone.0064733.t003
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